The patent for the most expensive diabetes drug has been revoked. Are cheaper alternatives closer to reimbursement?
A patent for dapagliflozin, a leading diabetes medication, has been revoked, potentially paving the way for cheaper generic versions to be reimbursed in Poland.
India: Generic versions of Ozempic and Wegony Coming – They Will Be 60% Cheaper
An Indian pharmaceutical company is set to launch generic versions of obesity drugs Ozempic and Wegony at significantly reduced prices in India.
What do we know about Farmacias Similares' expansion to Japan?
Farmacias Similares, the largest pharmacy chain in Latin America, is expanding into Japan using a digital marketing model and local adaptations to its brand.
The Dangers of Drug Price Cuts Based on Fiscal Logic
The South Korean government's policy to reduce drug prices raises concerns about its potential negative impact on public health and the domestic pharmaceutical industry's sustainability.
Are Generic Drugs Cut to Create New Drugs? … It’s a Misdiagnosis
The ongoing debate surrounding the Ministry of Health and Welfare's proposal to lower the prices of generic drugs in South Korea has raised concerns about its implications for new drug development and the pharmaceutical industry.
Europe Gets Hooked on Chinese Drugs: Journey to the Starting Point of the New Silk Road of Medications
The city of Suzhou, known for its ancient canals and cultural significance, is now the heart of China's pharmaceutical industry, producing active ingredients and generic drugs for markets worldwide.
The Patents for Weight Loss Drugs Expire: Generics Are Coming
The expiration of patents for weight loss drugs is paving the way for the introduction of generic alternatives in the global obesity medication market.